Investor Presentaiton

STRATEGIC DELIVERABLES PROGRESS SINCE THE LAST EARNINGS CALL Invest in Current Portfolio Gross Margin: Non-GAAP gross margin of 79.8% in Q2 SG&A: 18% increase in Q2 primarily driven by recent and upcoming product launches Invest in Future Innovation • R&D: 32% increase in Q2 driven by late- stage assets and early-stage research CAPEX: Commercial production initiated at the RTP facility Business Development: Completed the divestitures of Baqsimi and olanzapine; announced acquisitions of DICE Therapeutics, Sigilon Therapeutics and Versanis Bio Return Capital to Shareholders via: Deliver Revenue Growth Lilly 喝 Excluding Baqsimi® and sales of COVID-19 antibodies¹, revenue grew 22% in Q2, driven by volume growth of 23% Together, New Products and Growth Products2 contributed. approximately 26 percentage points of volume growth in Q2 Speed Life-Changing Medicines Dividend: Distributed over $1 billion in Q2 Announced positive results in the Phase 3 TRAILBLAZER- ALZ 2 study and the submission of donanemab for traditional approval to the FDA and in the EU; Announced the completed submission of tirzepatide in chronic weight management to the FDA and tirzepatide SURMOUNT-3 and -4 positive topline results; and Announced the approval of mirikizumab in the EU and re- submission in the U.S. Share Repurchase: $750 million YTD 1 Sales for COVID-19 antibodies include bamlanivimab, etesevimab and bebtelovimab sold pursuant to Emergency Use Authorization or similar regulatory authorizations 2 Refer to slide 9 for a list of New Products and Growth Products Not for promotional use 2023 Q2 EARNINGS 4

View entire presentation